好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Xanthogranulomatous Hypertrophic Pachymeningitis in a Patient with Lipoprotein X Syndrome: a Rare Case Report
Autoimmune Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
2-013
To report a rare case of a patient with lipoprotein X (LpX) syndrome and xanthogranulomatous hypertrophic pachymeningitis (XHP).
LpX is an abnormal lipoprotein that can be seen in cholestatic liver disease. Patients with LpX are at risk for xanthomatosis characterized by the accumulation of excess lipids in different organs. This is the first known report of XHP in a patient with LpX syndrome.
Case report.

A 41-year-old Hispanic female with history of primary biliary cholangitis/autoimmune hepatitis overlap, presented with first-time seizure. Brain magnetic resonance imaging raised a suspicion of right frontal hypertrophic pachymeningitis (HP) (1.2 cm) with midline shift. Cerebrospinal fluid (CSF) studies showed: normal cell count, normal CSF protein, normal angiotensin converting enzyme, negative CSF oligoclonal immunoglobulin G (IgG) bands, elevated CSF IgG index (1.6) and elevated CSF soluble interleukin-2 (sIL-2) receptor (107.0 pg/mL; reference,  £26.8). CSF hematopathology analysis reported no blasts or malignant cells, and infectious CSF work-up was negative. Blood work up revealed: elevated sIL-2 receptor (1133.0 pg/ml; reference, 175.3-858.2), positive antinuclear antibody (Ab) (≥1:2560), positive centromere IgG, negative antineutrophil cytoplasmic Ab, negative anti- Sjögren's-syndrome-related antigen A/B Abs, negative rheumatoid factor, normal IgG4 level, and negative infectious work-up. Lipoprotein metabolism profile evaluation showed elevated total cholesterol, low-density lipoprotein (LDL) and triglycerides, low high-density lipoprotein, and the presence of LpX. Genetic familial hypercholesterolemia and comprehensive lipidemia panels were unrevealing. Dural biopsy was suggestive of xanthogranulomatous inflammation and staining identified no fungi, spirochetes, acid-fast bacteria, or other bacteria. Skin biopsy confirmed xanthogranulomas. The patient was treated with immunosuppression, antiseizure medications, cholesterol and trygliceride- lowering agents, LDL pheresis, however due to multiorgan failure and infectious complications the outcome was poor.

This case describes previously unreported presentation of LpX with XHP. Patients presenting with HP and cholestatic liver disease should be evaluated for LpX syndrome.
Authors/Disclosures
Nikash Shankar, MD (UNC Hospitals)
PRESENTER
Dr. Shankar has received personal compensation for serving as an employee of Medstar Georgetown.
Vorapat Vorapanya, MD An immediate family member of Ms. Vorapanya has received personal compensation for serving as an employee of Elevance Health.
Benjamin Cho Benjamin Cho has nothing to disclose.
Alfred S. Barritt IV, MD Dr. Barritt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Madrigal.
Robert S. Hagan, MD, PhD Dr. Hagan has nothing to disclose.
Jason R. Mock, MD, PhD Dr. Mock has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Parker Poe Law Firm. The institution of Dr. Mock has received research support from NIH .
George S. DeCherney, MD Prof. DeCherney has nothing to disclose.
William A. Fischer II, MD Dr. Fischer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clario. The institution of Dr. Fischer has received research support from NIH. The institution of Dr. Fischer has received research support from CEPI.
Irena Dujmovic Basuroski, MD, PhD (University of North Carolina At Chapel Hill) The institution of Dr. Dujmovic Basuroski has received research support from Alexion Pharmaceuticals, Inc. The institution of Dr. Dujmovic Basuroski has received research support from Biogen MA Inc. The institution of Dr. Dujmovic Basuroski has received research support from EMD Serono Research and Development Institute, Inc . The institution of Dr. Dujmovic Basuroski has received research support from Celgene Corporation/Bristol-Myers Squibb. The institution of Dr. Dujmovic Basuroski has received research support from The Bodford Family Transverse Myelitis Center Fund. The institution of Dr. Dujmovic Basuroski has received research support from CorEvitas, LLC. The institution of Dr. Dujmovic Basuroski has received research support from Novartis. The institution of Dr. Dujmovic Basuroski has received research support from Ad Scientiam. Dr. Dujmovic Basuroski has received personal compensation in the range of $0-$499 for serving as a Travel -related expenses to attend clinical trial investigator meeting with Novartis. Dr. Dujmovic Basuroski has received personal compensation in the range of $500-$4,999 for serving as a International Clinical Consortium Member, Travel -related expenses to attend the meeting with The Guthy-Jackson Charitable Foundation.